CCO Independent Conference Coverage
2008 American Society of Clinical Oncology Annual Meeting*
May 30-June 3, 2008 | McCormick Place, Chicago, Illinois
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Breast Cancer
|
Track 1 of 6
|
Gastrointestinal Cancers
|
Track 2 of 6
|
Genitourinary Cancers
|
Track 3 of 6
|
Hematologic Malignancies
|
Track 4 of 6
|
Ovarian Cancer
|
Track 6 of 6
|
Expert Highlights
Choose a highlight from the list below:
|
Expert Highlight: Breast Cancer
Kathy D. Miller, MD, provides an update on the top issues in adjuvant therapy including hormone therapy, bone loss treatments, and vitamin D status. She also discusses the impact of biologic agents targeting VEGF and EGFR on therapy for metastatic disease. (12 minutes)
Windows Media 24.9 MB
Quicktime Video 17.2 MB
iPod Video 141.6 MB
Audio 11.3 MB
|
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
In SWOG Phase III Trial, Irinotecan/Cisplatin Fails to Demonstrate Survival Advantage Over Etoposide/Cisplatin in Extensive SCLC
In contrast to JCOG 9511, the SWOG S0124 phase III trial failed to demonstrate response or survival advantages for irinotecan/cisplatin over the current standard etoposide/cisplatin in treatment of patients with extensive small-cell lung cancer
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|